Falnidamol (Standard)

Falnidamol (Standard) is the analytical standard of Falnidamol. This product is intended for research and analytical applications. Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM) . Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity[1][2].

Product Specifications

CAS Number

[196612-93-8]

Product Name Alternative

BIBX 1382 (Standard)

UNSPSC

12352005

Target

EGFR; Reference Standards

Related Pathways

JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

ClC1=CC(NC2=NC=NC3=CN=C(NC(CC4)CCN4C)N=C23)=CC=C1F

Molecular Formula

C18H19ClFN7

Molecular Weight

387.84

References & Citations

[1]Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311 (2) :502-9.|[2]Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38 (8) :1072-80.